Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Early Study Results Find High Proportion of Young Lung Cancer Patients With Targetable Mutations

Early Study Results Find High Proportion of Young Lung Cancer Patients With Targetable Mutations

Sep 22, 2015
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – Researchers hoping to uncover the genetic factors underlying lung cancer in young and otherwise healthy adults have reported preliminary results showing that 76 percent of participants in a study had druggable driver mutations in their tumors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
20
Featured Webinar

Crystal Digital PCR for Accurate Chimerism Monitoring after Stem Cell Transplantation

Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

Oct
21
Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Oct
22
Featured Webinar

Adoption of Broad NGS Profiling for HRR Deficiency: Looking Beyond BRCA, SNPs, and Indels

Sponsored by
Sophia Genetics

This webinar will share the Lorraine Cancer Institute's experience in implementing a novel targeted solution to accurately assess homologous recombination repair (HRR) deficiency by analyzing a series of genes, beyond BRCA, and calling multiple types of variants, including copy number variants (CNVs).

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

  2. NGS-Based Profiling May Guide Treatment for Patients With Cancers of Unknown Primary

  3. Disparity in Microsatellite Instability Testing Suggests Need to Close Socioeconomic Access Gaps

    Premium

  4. Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests

  5. Pancreatic Cancer Subtype With Poor Outcomes Shows Low Methylation, High Interferon Signature

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.